肝硬化合并门静脉血栓治疗进展

李晓珂; 杨新乐; 王彤; 薛舒文; 郭晓林; 季慧范

doi:10.3969/j.issn.1001-5256.2021.07.045

肝硬化合并门静脉血栓治疗进展

DOI: 10.3969/j.issn.1001-5256.2021.07.045

吉林大学第一医院肝胆胰内科，长春 130021

利益冲突声明：所有作者均声明不存在利益冲突。

作者贡献声明：李晓珂负责选题，分析资料，撰写文章; 杨新乐、王彤、薛舒文参与选题，收集资料; 郭晓林、季慧范拟定写作思路，指导撰写文章并最终定稿。

详细信息

通信作者:
季慧范，jihf@jlu.edu.cn

中图分类号: R575.2
计量
- 文章访问数: 654
- HTML全文浏览量: 147
- PDF下载量: 148
- 被引次数: 0
出版历程
- 收稿日期: 2020-12-07
- 录用日期: 2021-01-22
- 出版日期: 2021-07-20

Advances in the treatment of liver cirrhosis with portal vein thrombosis

Department of Hepatobiliary and Pancreatic Medicine, The First Hospital of Jilin University, Changchun 130021, China

摘要

摘要: 门静脉血栓(PVT)是肝硬化的常见并发症之一，由于肝硬化存在凝血功能障碍和出血风险，临床上对于肝硬化合并PVT的治疗存在诸多争议。PVT常用治疗方法包括抗凝、介入和溶栓，重点阐述了肝硬化合并PVT的治疗现状，以期为临床制订规范合理的治疗策略提供帮助。
- 肝硬化 /
- 静脉血栓形成 /
- 治疗学
Abstract: Portal vein thrombosis (PVT) is one of the most common complications of liver cirrhosis. Due to coagulation disorder and the risk of bleeding in liver cirrhosis, there are many controversies over the treatment of liver cirrhosis with PVT in clinical practice. Common therapies for PVT include anticoagulant therapy, intervention, and thrombolysis. This article elaborates on the current status of the treatment of liver cirrhosis with PVT, in order to provide help for the development of standard and reasonable clinical treatment strategies.
- Liver Cirrhosis /
- Venous Thrombosis /
- Therapeutics

HTML全文

参考文献(35)

[1]	NORONHA FERREIRA C, MARINHO RT, CORTEZ-PINTO H, et al. Incidence, predictive factors and clinical significance of development of portal vein thrombosis in cirrhosis: A prospective study[J]. Liver Int, 2019, 39(8): 1459-1467. DOI: 10.1111/liv.14121.
[2]	NICOARǍ-FARCǍU O, SOY G, MAGAZ M, et al. New insights into the pathogenesis, risk factors, and treatment of portal vein thrombosis in patients with cirrhosis[J]. Semin Thromb Hemost, 2020, 46(6): 673-681. DOI: 10.1055/s-0040-1715473.
[3]	FACCIA M, AINORA ME, PONZIANI FR, et al. Portal vein thrombosis in cirrhosis: Why a well-known complication is still matter of debate[J]. World J Gastroenterol, 2019, 25(31): 4437-4451. DOI: 10.3748/wjg.v25.i31.4437.
[4]	NERY F, CHEVRET S, CONDAT B, et al. Causes and consequences of portal vein thrombosis in 1, 243 patients with cirrhosis: Results of a longitudinal study[J]. Hepatology, 2015, 61(2): 660-667. DOI: 10.1002/hep.27546.
[5]	VIOLI F, CORAZZA GR, CALDWELL SH, et al. Portal vein thrombosis relevance on liver cirrhosis: Italian venous thrombotic events registry[J]. Intern Emerg Med, 2016, 11(8): 1059-1066. DOI: 10.1007/s11739-016-1416-8.
[6]	STINE JG, NORTHUP PG. Management of non-tumoral portal vein thrombosis in patients with cirrhosis[J]. Dig Dis Sci, 2019, 64(3): 619-626. DOI: 10.1007/s10620-018-5427-3.
[7]	COOL J, ROSENBLATT R, KUMAR S, et al. Portal vein thrombosis prevalence and associated mortality in cirrhosis in a nationally representative inpatient cohort[J]. J Gastroenterol Hepatol, 2019, 34(6): 1088-1092. DOI: 10.1111/jgh.14501.
[8]	Hepatobiliary Disease Study Group, Chinese Society of Gastroenterology, Chinese Medical Association. Consensus for management of portal vein thrombosis in liver cirrhosis (2020, Shanghai)[J]. J Clin Hepatol, 2020, 36(12): 2667-2674. DOI: 10.3969/j.issn.1001-5256.2020.12.007. 中华医学会消化病学分会肝胆疾病学组. 肝硬化门静脉血栓管理专家共识(2020年, 上海)[J]. 临床肝胆病杂志, 2020, 36(12): 2667-2674. DOI: 10.3969/j.issn.1001-5256.2020.12.007.
[9]	QI X, SU C, REN W, et al. Association between portal vein thrombosis and risk of bleeding in liver cirrhosis: A systematic review of the literature[J]. Clin Res Hepatol Gastroenterol, 2015, 39(6): 683-691. DOI: 10.1016/j.clinre.2015.02.012.
[10]	STINE JG, SHAH PM, CORNELLA SL, et al. Portal vein thrombosis, mortality and hepatic decompensation in patients with cirrhosis: A meta-analysis[J]. World J Hepatol, 2015, 7(27): 2774-2780. DOI: 10.4254/wjh.v7.i27.2774.
[11]	MARUYAMA H, OKUGAWA H, TAKAHASHI M, et al. De novo portal vein thrombosis in virus-related cirrhosis: Predictive factors and long-term outcomes[J]. Am J Gastroenterol, 2013, 108(4): 568-574. DOI: 10.1038/ajg.2012.452.
[12]	LYU Y, HAN GH, FAN DM. progress of cirrhosis with portal vein thrombosis[J]. Chin J Dig, 2017, 37(8): 568-570. DOI: 10.3760/cma.j.issn.0254-1432.2017.08.015. 吕勇, 韩国宏, 樊代明. 肝硬化门静脉血栓研究进展[J]. 中华消化杂志, 2017, 37(8): 568-570. DOI: 10.3760/cma.j.issn.0254-1432.2017.08.015.
[13]	European Association for the Study of the Liver. EASL clinical practice guidelines: Vascular diseases of the liver[J]. J Hepatol, 2016, 64(1): 179-202. DOI: 10.1016/j.jhep.2015.07.040.
[14]	LIU PY, ZHOU Q, LIU CY, et al. The controversy and challenge of anticoagulation therapy for portal vein thrombosis in cirrhosis[J]. Chin J Intern Med, 2018, 57(7): 532-534. DOI: 10.3760/cma.j.issn.0578-1426.2018.07.015. 刘培焱, 周琦, 刘春燕, 等. 肝硬化门静脉血栓抗凝治疗及其争议与挑战[J]. 中华内科杂志, 2018, 57(7): 532-534. DOI: 10.3760/cma.j.issn.0578-1426.2018.07.015.
[15]	MOHAN BP, ARAVAMUDAN VM, KHAN SR, et al. Treatment response and bleeding events associated with anticoagulant therapy of portal vein thrombosis in cirrhotic patients: Systematic review and meta-analysis[J]. Ann Gastroenterol, 2020, 33(5): 521-527. DOI: 10.20524/aog.2020.0503.
[16]	SCHEINER B, STAMMET PR, POKORNY S, et al. Anticoagulation in non-malignant portal vein thrombosis is safe and improves hepatic function[J]. Wien Klin Wochenschr, 2018, 130(13-14): 446-455. DOI: 10.1007/s00508-018-1351-y.
[17]	CERINI F, VILASECA M, LAFOZ E, et al. Enoxaparin reduces hepatic vascular resistance and portal pressure in cirrhotic rats[J]. J Hepatol, 2016, 64(4): 834-842. DOI: 10.1016/j.jhep.2015.12.003.
[18]	NORONHA FERREIRA C, REIS D, CORTEZ-PINTO H, et al. Anticoagulation in cirrhosis and portal vein thrombosis is safe and improves prognosis in advanced cirrhosis[J]. Dig Dis Sci, 2019, 64(9): 2671-2683. DOI: 10.1007/s10620-019-05572-z.
[19]	AHMED Z, SINGAL AK, KAMATH PS. Anticoagulants and their monitoring[J]. Clin Liver Dis (Hoboken), 2020, 16(4): 146-148. DOI: 10.1002/cld.946.
[20]	TURCO L, de RAUCOURT E, VALLA DC, et al. Anticoagulation in the cirrhotic patient[J]. JHEP Rep, 2019, 1(3): 227-239. DOI: 10.1016/j.jhepr.2019.02.006.
[21]	LIU JX, LI WT, ZHANG ZZ, et al. progress on pharmacological mechanism of LMWH and its clinical indications[J]. J Pharm Res, 2015, 34(7): 420-421, 424. https://www.cnki.com.cn/Article/CJFDTOTAL-SDYG201507017.htm 刘晋仙, 李玮涛, 张在忠, 等. 低分子肝素药理学机制及适应证研究进展[J]. 药学研究, 2015, 34(7): 420-421, 424. https://www.cnki.com.cn/Article/CJFDTOTAL-SDYG201507017.htm
[22]	VILLA E, CAMMÀ C, MARIETTA M, et al. Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis[J]. Gastroenterology, 2012, 143(5): 1253-1260. DOI: 10.1053/j.gastro.2012.07.018.
[23]	CUI SB, SHU RH, YAN SP, et al. Efficacy and safety of anticoagulation therapy with different doses of enoxaparin for portal vein thrombosis in cirrhotic patients with hepatitis B[J]. Eur J Gastroenterol Hepatol, 2015, 27(8): 914-919. DOI: 10.1097/MEG.0000000000000351.
[24]	ZHOU T, SUN X, ZHOU T, et al. Efficacy and safety of nadroparin calcium-warfarin sequential anticoagulation in portal vein thrombosis in cirrhotic patients: A randomized controlled trial[J]. Clin Transl Gastroenterol, 2020, 11(9): e00228. DOI: 10.14309/ctg.0000000000000228.
[25]	AI MH, DONG WG, TAN XP, et al. Efficacy and safety study of direct-acting oral anticoagulants for the treatment of chronic portal vein thrombosis in patients with liver cirrhosis[J]. Eur J Gastroenterol Hepatol, 2020, 32(10): 1395-1400. DOI: 10.1097/MEG.0000000000001846.
[26]	RODRIGUEZ-CASTRO KI, VITALE A, FADIN M, et al. A prediction model for successful anticoagulation in cirrhotic portal vein thrombosis[J]. Eur J Gastroenterol Hepatol, 2019, 31(1): 34-42. DOI: 10.1097/MEG.0000000000001237.
[27]	The Chinese College of Interventionalists. CCI clinical practice guidelines: Management of TIPS for portal hypertension (2019 edition)[J]. J Clin Hepatol, 2019, 35(12): 2694-2699. DOI: 10.3969/j.issn.1001-5256.2019.12.010. 中国医师协会介入医师分会. 中国门静脉高压经颈静脉肝内门体分流术临床实践指南(2019年版)[J]. 临床肝胆病杂志, 2019, 35(12): 2694-2699. DOI: 10.3969/j.issn.1001-5256.2019.12.010.
[28]	DAVIS J, OGURICK AG, ROTHERMEL CE, et al. Anticoagulation and transjugular intrahepatic portosystemic shunting for treatment of portal vein thrombosis in cirrhosis: A systematic review and meta-analysis[J]. Clin Appl Thromb Hemost, 2019, 25: 1076029619888026. DOI: 10.1177/1076029619888026.
[29]	CAI GP, HUA ZH, XU P, et al. TIPS access to portal vein thrombolysis[J]. Chin J Gen Surg, 2019, 34(4): 336-339. DOI: 10.3760/cma.j.issn.1007-631X.2019.04.013. 蔡高坡, 化召辉, 徐鹏, 等. 经TIPS途径治疗门静脉系统血栓[J]. 中华普通外科杂志, 2019, 34(4): 336-339. DOI: 10.3760/cma.j.issn.1007-631X.2019.04.013.
[30]	VALENTIN N, KORRAPATI P, CONSTANTINO J, et al. The role of transjugular intrahepatic portosystemic shunt in the management of portal vein thrombosis: A systematic review and meta-analysis[J]. Eur J Gastroenterol Hepatol, 2018, 30(10): 1187-1193. DOI: 10.1097/MEG.0000000000001219.
[31]	MEROLA J, FORTUNE BE, DENG Y, et al. Transjugular intrahepatic portosystemic shunt creation for cirrhotic portal hypertension is well tolerated among patients with portal vein thrombosis[J]. Eur J Gastroenterol Hepatol, 2018, 30(6): 668-675. DOI: 10.1097/MEG.0000000000001097.
[32]	LUCA A, MIRAGLIA R, CARUSO S, et al. Short- and long-term effects of the transjugular intrahepatic portosystemic shunt on portal vein thrombosis in patients with cirrhosis[J]. Gut, 2011, 60(6): 846-852. DOI: 10.1136/gut.2010.228023.
[33]	WANG ZC, GU EL, WANG SP, et al. The treatment progress of cirrhosis with portal vein thrombosis[J]. Mod J Integr Tradit Chin West Med, 2016, 25(22): 2502-2505. DOI: 10.3969/j.issn.1008-8849.2016.22. 王忠成, 顾尔莉, 王世蓬, 等.肝硬化门静脉血栓症的治疗进展[J]. 现代中西医结合杂志, 2016, 25(22): 2502-2505. DOI: 10.3969/j.issn.1008-8849.2016.22.
[34]	LIU YJ. Prophylaxis and management of patients with portal vein thrombosis complicting liver cirrhosis[J]. J Prac Hepatol, 2019, 22(4): 605-608. DOI: 10.3969/j.issn.1672-5069.2019.04.039. 刘彦君. 肝硬化并发门静脉血栓防治研究进展[J]. 实用肝脏病杂志, 2019, 22(4): 605-608. DOI: 10.3969/j.issn.1672-5069.2019.04.039.
[35]	de SANTIS A, MOSCATELLI R, CATALANO C, et al. Systemic thrombolysis of portal vein thrombosis in cirrhotic patients: A pilot study[J]. Dig Liver Dis, 2010, 42(6): 451-455. DOI: 10.1016/j.dld.2009.08.009.